Shots: 

• Post FDA approval- Lenvima receives EU approval for oral RTKi for the treatment of advanced or unresectable HCC
• The approval is based on REFLECT study results: (Lenvima vs Sorafenib): mOS (13.6 vs 12.3 mos)- mPFS (7.3 vs 3.6 mos); ORR (41% vs 12%); mTTP (7.4 vs 3.7mos)
• Lenvima is approved for thyroid cancer in over 50 countries including in EU- Japan and the US- and in EU it is available as Kisplyx in combination with everolimus for the 2L treatment of renal cell carcinoma 

Ref: Eisai | Image: Merck